Drug Trial Radar · NCT06611319
ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,932
Planned (sponsor's estimate)
Start
Nov 26, 2024
Primary completion
Mar 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Prof. Stavros Konstantinides, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Surgical hip replacement (total hip arthroplasty, THA) is associated with a high risk of venous thromboembolism, but the appropriate duration of postoperative medical thromboprophylaxis ("anticoagulation") remains highly controversial. The international randomized controlled trial (RCT) "ENhanced recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis after primary Hip Arthroplasty" (ENABLE-Hip) will enroll patients undergoing elective THA that are eligible for early mobilization after surgery. The trial will compare a regimen of short-duration (10-day) postoperative anticoagulation (experimental group) to standard-duration (35-day) postoperative anticoagulation (control group) using the direct oral anticoagulant Rivaroxaban (brand name: Xarelto) at the recommended dose. Thus, ENABLE-Hip will be the first major RCT to directly test an overall reduction in the duration of post-THA thromboprophylaxis instead of replacing one antithrombotic drug or regimen by another. Follow-up visits after hospital discharge will be on day 35 and on day 90 after surgery. The primary outcome is acute symptomatic proximal deep vein thrombosis, or symptomatic or fatal pulmonary embolism, within 90 days after surgery. If ENABLE-Hip will demonstrate 'non-inferiority' of the experimental intervention, its benefits will be obvious, as patients are spared many days of unnecessary (and potentially harmful in terms of bleeding risk) anticoagulation.
Conditions
- Hip Arthroplasty, Total
- Prevention of Venous Thromboembolism
Interventions
Prevention of Venous ThromboembolismDrug
Direct oral anticoagulant
Placebo Oral TabletDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy endpoint is the rate of acute symptomatic or fatal VTETime frame: within 90 days after surgery
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Kepler University Medical Center, Orthopedics and Traumatology
Linz, Upper Austria, Austria · Recruiting
Evangelical Forest Hospital Berlin - Orthopaedics and Trauma Surgery
Berlin, Germany · Recruiting
Sana Clinics Sommerfeld, Dpt. for Surgical Orthopaedics
Kremmen, Brandenburg, Germany · Recruiting
GPR Rüsselsheim Health and Care Center
Rüsselsheim am Main, Hesse, Germany · Recruiting
University Medical Center Mainz, Center for Orthopedics and Trauma Surgery
Mainz, Rhineland-Palatine, Germany · Recruiting
University Medical Center Dresden, University Center for Orthopaedics, Trauma & Plastic Surgery
Dresden, Saxony, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.